LENEXA, Kan., Feb. 19, 2011 /PRNewswire/ — CompanDX Ltd.,
bioinformatics partner for the life sciences industry, and Clinical
Reference Laboratory, Inc. (CRL), provider of laboratory testing
services in molecular diagnostics and clinical trials, today
announced they entered into a multi-year agreement to collaborate
in the development and support of biomarker panels and companion
diagnostic development for pharmaceutical, biotech and academic
clients worldwide. Under the terms of the agreement, CompanDX will
continue its trailblazing bioinformatics work on its “Distiller”
platform, which includes the development of the first “Time to
Event” breast cancer signature supported by CRL’s CLIA-certified
laboratory services.
The agreement today paves the way for CRL and CompanDX to
deliver “discovery to validated test” services to their respective
clients. “CRL has a strong, long-standing reputation for
providing state-of-the-art CLIA-certified testing services. In
forging this relationship it allows us to reach both upstream and
downstream to significantly broadening our reach into the growing
market of Molecular Diagnostics, Stratified Clinical Trails and
Personalized Medicine,” said AD Sutton, CEO, CompanDX.
“Clients are looking for our help to support their clinical
development programmes either by reducing the complexity of genomic
or proteomic data or by proving innovative MDx tests that will
allow them to stratify clinical trials. CRL brings a level of
expertise in the design and delivery of MDx tests that ideally
compliments our innovative approach.”
CRL’s Executive Director of Molecular Diagnostics, Dr. Heather
Fehling agrees, “CRL and CompanDX created a powerful team to help
meet client’s challenges in identifying meaningful biomarker panels
and developing novel MDx testing for those panels. CRL is
excited to link its years of CLIA-certified laboratory experience
with CompanDX’s cutting edge bioinformatics tools to cre
‘/>”/>
